

Curriculum Vitae

PERSONAL DATA

Name: John J. Zone
Birth Place: Wayland, New York USA
Citizenship: United States

EDUCATION

<u>Years</u>	<u>Degree</u>	<u>Institution (Area of Study)</u>
1963 - 1967	BS	University of Notre Dame (Premedical Sciences) South Bend, IN
1967 - 1971	MD	SUNY at Syracuse (Medicine) Syracuse, NY
1971 - 1972	Intern	SUNY at Syracuse (Internal Medicine) Syracuse, NY
1972 - 1975	Resident	SUNY at Syracuse (Internal Medicine) Syracuse, NY
1975 - 1978	Resident	SUNY - Buffalo (Dermatology) Buffalo, NY

BOARD CERTIFICATIONS

06/19/1974 American Board of Internal Medicine (Int Med), Certified - does not expire
10/30/1978 American Board of Dermatology (Derm), Certified - does not expire
11/05/1985 American Board of Dermatology (Sub: Clin&Lab Derm Imm), Certified - does not expire

CURRENT LICENSES/CERTIFICATIONS

1999-2010 Controlled Substance (UT)
1999-2010 State License (UT)
2006-2009 DEA Certificate (UT)

ACADEMIC HISTORY

Dermatology

01/01/1978 Hire, Tenure Track, Assistant Professor
07/01/1983 Promotion, Associate Professor
07/01/1983 Tenure
07/01/1990 Promotion, Professor

PROFESSIONAL EXPERIENCE

Full Time Positions

1978 -1983 Assistant Professor, University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, Utah
1978 - Present Chief of Dermatology Section, Veteran's Administration Medical Center, Salt Lake City, Utah
1983 -1990 Associate Professor, University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, Utah
1987 -1996 Head, Division of Dermatology, University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, Utah
1990 -1996 Professor, University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, Utah
1996 - Present Professor, University of Utah School of Medicine, Department of Dermatology, Salt Lake City, Utah

1996 - Present Chairman, University of Utah School of Medicine, Department of Dermatology, Salt Lake City, Utah

Editorial Experience

1996 -1998 Editor for Dermatology Section, MKSAP XI

2005 Consultant to the Editor for Goodman and Gillman's "The Pharmacological Basis of Therapeutics", Eleventh Edition

Reviewer Experience

Reviewer for Archives of Dermatology

Reviewer for Pediatric Dermatology

Reviewer for Journal of the American Academy of Dermatology

Reviewer for Dermatology Foundation Scientific Committee

Reviewer for Journal of Clinical Investigation

Reviewer for Journal of Immunology

Reviewer for New England Journal

Reviewer for British Journal of Dermatology

Reviewer for International Journal of Dermatology

Reviewer for Journal of Investigative Dermatology

Reviewer for Journal of Obstetrics and Gynecology

Reviewer for Experimental Dermatology

SCHOLASTIC HONORS

1970 Alpha Omega Alpha

1995 -2008 Best Doctors in America

ADMINISTRATIVE EXPERIENCE

Administrative Duties

1978 - Present Head of Section of Dermatology, Veteran's Administration Medical Center, Salt Lake City.

1987 -1996 Head of Division of Dermatology, University of Utah School of Medicine.

1996 - Present Chairman of Department of Dermatology, University of Utah School of Medicine.

1998 -2000 President-Elect, University of Utah Hospital Medical Staff.

2000 -2002 President, University of Utah Hospital Medical Staff.

2006 - Present Chairman, Space Committee, University of Utah Hospitals and Clinics

Professional Organization & Scientific Activities

1984 -1985 President-Elect, Society for Investigative Dermatology, Western Region

1985 -1986 President, Society for Investigative Dermatology, Western Region

1991 -1993 Member, American Academy of Dermatology, Task Force on Internal Medicine

1991 -1993 Board Member, American Professors of Dermatology

1991 -1992 Committee Member, American College of Physicians, Medical Knowledge Self Assessment Program IX

1993 - Present Member, Dermatology Foundation, Leader's Society

1993 -1999 Board Member, American Professors of Dermatology

1995 -1996 President, National Association of Veterans Administration Dermatologists

1996 -1999 Secretary/Treasurer, American Professors of Dermatology

1996 -2002 Committee Member, Intermountain Tissue Center Advisory Committee

Grant Review Committee/Study Section

1987 Ad hoc study section member NIAASD

1987 Veterans Administration Review Board for Immunology

1989 Veterans Administration Review Board for Immunology

1990 Ad hoc study section member NIAASD

1991 -1996 Veterans Administration Review Board for Immunology

1992 Ad hoc study section member NIAASD

1993 -1995 Committee Member, Dermatology Foundation, Scientific Review Committee

1996 -1998 Chair, Dermatology Foundation, Scientific Review Committee

1997 Ad hoc study section member NIAASD
2000 Veterans Administration Review Board for Immunology

Symposium/Meeting Chair/Coordinator

1990 -1994 Internal Medicine Symposium, American Academy of Dermatology
2001 -2005 American Academy of Dermatology, National meeting, Internal Medicine course

PROFESSIONAL COMMUNITY ACTIVITIES

1989 -1995 Member, Veterans Administration Medical Center, Health Care Improvement Committee
1993 -2000 Committee Member, Veterans Administration Medical Center, Clinical Performance Evaluation Committee
1995 -1996 Committee Member, Veterans Administration Medical Center, Chief of Staff Search Committee
1995 -1998 Chairman, Veterans Administration Medical Center, Health Care Improvement Committee
1997 -1999 Facilitator, World Health Organization, Evaluate Sudan health status
1998 -2002 Committee Member, Veterans Administration Medical Center, Quality Executive Board

UNIVERSITY COMMUNITY ACTIVITIES

University Level

2001 -2002 Committee Member, Policy and Procedure Task Force

Health Sciences Level

1998 -2001 Committee Member, University of Utah Health Network, Operations Committee
1998 -2000 Committee Member, University of Utah Health Network, Academic Affairs Committee
1998 -2001 Committee Member, University of Utah Health Network, Board of Directors
1998 -2001 Committee Member, University of Utah Health Network, Finance Committee
1999 Chairman, Mission-Based Management, Steering Committee
1999 - Present Chairman, Mission-Based Management Advisory Committee
2000 - Present Committee Member, University of Utah Medical Group, Board of Directors
2006 - Present Committee Member, Health System Executive Council
2008 - Present Committee Member, Health Sciences Center, Exceptional Patient Experience - Organizational Culture Group

University Hospitals & Clinics

1987 - Present Committee Member, Ambulatory Care Committee, University of Utah Medical Center
1991 - Present Committee Member, Ambulatory Care Medical Directors Committee
1998 -2000 President-Elect, University Hospital Medical Board, University of Utah Hospital Medical Staff
2000 -2002 President, University Hospital Medical Board, University of Utah Hospital Medical Staff
2000 -2002 Committee Member, Bylaws Committee, University of Utah Medical Center
2001 - Present Committee Member, Hospital Space Committee, University of Utah
2002 -2007 Committee Member, University Hospital, Capital Equipment Committee
2007 - Present Committee Member, Hospital Expansion Steering Committee
2007 - Present Committee Member, Ambulatory Care Committee, Initiative Steering Committee
2008 - Present Committee Member, University Hospital, Chief Medical Information Officer, Search Committee
2008 - Present Committee Member, University Hospital, Information Technology Executive Steering Committee

College Level

1996 - Present Committee Member, School of Medicine Executive Committee
1996 - Present Committee Member, School of Medicine Medical Sciences Council
2000 - Present Committee Member, University of Utah Medical Group Board of Directors

Department Level

1996 - Present Department Chair, Dermatology, University of Utah School of Medicine
1998 -2000 Chairman, Surgery, Search Committee
1998 -2000 Committee Member, Huntsman Cancer Institute, Medical Director and Chief of Oncology, Search Committee
1999 -2008 Director, Huntsman Cancer Institute, Multidisciplinary Melanoma Program
1999 -2006 Executive Committee Member, Huntsman Cancer Institute
2001 -2006 Committee Member, Huntsman Cancer Institute, Cancer Center Support Grant Committee

2002 -2003 Committee Member, Gerontology, Search Committee
2002 -2003 Committee Member, Pathology, Search Committee
2003 -2004 Co-Chairman, Internal Medicine, Search Committee
2005 -2006 Committee Member, Huntsman Cancer Institute, Search Committee for Director

CURRENT MEMBERSHIPS IN PROFESSIONAL SOCIETIES

American Academy of Dermatology
Dermatology Foundation
Salt Lake County Medical Society
Society for Investigative Dermatology
Utah Medical Association
American Federation for Clinical Research
Western Society for Clinical Investigation
Association of Professors of Dermatology
American Dermatologic Association
Intermountain Dermatology Society
Utah Dermatology Society

FUNDING

Active Grants

07/01/06 - 06/30/09 Medical Dermatology Career Development Award on the Pathogenesis of Dermatitis Herpetiformis
Principal Investigator: Christopher M. Hull
Direct Costs: \$165,000 Total Costs: \$165,000
Dermatology Foundation
Role: Mentor

10/01/07 - 09/30/11 The role of IgE in Bullous Pemphigoid
Direct Costs: \$175,700 Total Costs: \$175,700
VA Medical Center/Salt Lake City (US Veteran's Administration)
Role: Co-Investigator

Past Grants

04/01/85 - 03/31/87 Dermatitis Herpetiformis - The Study of Immunoreactants in the Skin
Direct Costs: \$61,200 Total Costs: \$61,200
VA Merit Review
Role: Principal Investigator

04/01/85 - 01/22/91 Dermatitis Herpetiformis - Study of Immunoreactants in the Skin
Direct Costs: \$235,981 Total Costs: \$339,875
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Role: Principal Investigator

04/01/88 - 03/31/91 Dermatitis Herpetiformis - Characterization of IgA Extracted From Tissue
Direct Costs: \$143,700 Total Costs: \$143,700
VA Merit Review
Role: Principal Investigator

04/01/91 - 03/31/96 Pathogenesis of IgA Dermatoses
Direct Costs: \$213,800 Total Costs: \$213,800
VA Merit Review
Role: Principal Investigator

04/01/96 - 03/31/99 Dermatitis Herpetiformis (DH) - Pathogenesis of IgA Dermatoses
Direct Costs: \$766,400 Total Costs: \$766,400
VA Merit Review
Role: Principal Investigator

09/16/96 - 08/15/02 Mapping of Non-Hla Loci for Gluten Sensitive Enteropathy
Direct Costs: \$598,538 Total Costs: \$892,361
National Institute of Diabetes & Digestive & Kidney Diseases
Role: Principal Investigator

06/01/00 - 05/31/01 Development of an Animal Model for Bullous Pemphigoid
Direct Costs: \$15,000 Total Costs: \$15,000
VA Merit Review
Role: Principal Investigator

09/30/02 - 08/31/06 Mapping & Cloning of Non-HLA Genes for Celiac Disease
Prime Number Dk50678
Direct Costs: \$95,107 Total Costs: \$137,021
University of California, Irvine
Role: Principal Investigator

Past Contracts

04/01/81 - 08/08/85 Pathogenesis Of Dermatitis Herpetiformis.
Direct Costs: \$219,117 Total Costs: \$316,623
Johns Hopkins University
Role: Principal Investigator

09/01/88 - 12/26/91 A Comparative Study of the Safety and Efficacy of Abbott-56268 and Cefadroxil in the Treatment
of Patients with Mild to Moderate Skin and Skin Structure Infection
Direct Costs: \$19,060 Total Costs: \$22,700
Pharmaco Dynamics Research, Inc.
Role: Principal Investigator

01/01/89 - 09/05/89 Itch Receptors//Histimine Administration and Study of Anti-Pruritic Effect of Various Herbal
Remedies
Direct Costs: \$7,177 Total Costs: \$10,550
TOPICAL TESTING INC
Role: Principal Investigator

09/14/89 - 08/15/91 A Double-Blind Study of the Safety and Efficacy of Ru882 Versus its Vehicle Solution in Male
Patients With Acne Vulgaris
Direct Costs: \$36,083 Total Costs: \$43,300
Hoechst-Roussel Pharmaceutic Inc.
Role: Principal Investigator

01/19/90 - 07/28/91 A Multicenter Double Blind Evaluation Of Recombinant Human Basic Fibroblast Growth Factor In
The Treatment Of Venous Stasis And Diabetic Ulcers.
Direct Costs: \$41,667 Total Costs: \$50,000
Pharmaco Dynamics Research, Inc.
Role: Principal Investigator

06/10/91 - 10/31/94 A Randomized,Multi-Center Trial Comparing The Safety &Efficacy Of Standard Therapy Plus
Telio-Derm W/Standard Therapy Plus Saline Control In Patients W/Ulcers..
Direct Costs: \$37,530 Total Costs: \$37,530
TELIOS PHARMACEUTICALS
Role: Principal Investigator

11/01/92 - 09/19/96 Randomized Multi-Center Trial Comparing The Safety And Efficacy Of Telio-Derm W/Synthetic
Dressing Vs Saline Control W/Synthetic Dressing In Patients W/Venous L
Direct Costs: \$60,200 Total Costs: \$72,240
TELIOS PHARMACEUTICALS
Role: Principal Investigator

05/01/93 - 07/22/96 A Randomized, Multicenter Double-Blind Evaluation Of The Efficacy And Safety Of 12 Weeks
And 24 Weeks Treatment With Lamisis Vs. Placebo In The Treatment Of Ony
Direct Costs: \$60,337 Total Costs: \$76,930
Sandoz Foundation for Gerontological Research
Role: Principal Investigator

05/24/95 - 02/10/97 A Double-Blind, Multicenter Study Comparing Valacyclovir With Famciclovir For The Treatment
Of Uncomplicated Herpes Zoster In Immunocompetent Patients 50 Years
Direct Costs: \$18,628 Total Costs: \$23,750
QUINTILES PACIFIC INC
Role: Principal Investigator

- 06/01/98 - 05/31/99 Phase 2-3 Evaluation of Patients with Cutaneous T Cell Lymphoma
 Direct Costs: \$100,737 Total Costs: \$114,690
 Ligand Pharmaceuticals Inc.
 Role: Principal Investigator
- 06/04/99 - 06/30/01 Treatment Continuation Protocol of Targretin Capsules in Patients with Cutaneous T-Cell Lymphoma
 Direct Costs: \$2,500 Total Costs: \$2,500
 Ligand Pharmaceuticals Inc.
 Role: Principal Investigator

TEACHING RESPONSIBILITIES/ASSIGNMENTS

Courses Directed

1978 -1987 University of Utah School of Medicine, Dermatology Organ Systems

Course Lectures

2001 7010: Introduction to Medicine - Chairman 6(0.4)

Clinical Teaching

1989 - Present University of Utah, Department of Dermatology Residents Weekly Teaching Conference

Continuing Education

CE Courses Taught

1981 - Present Winter Skin Seminar
 1997 Co-Director, Winter Skin Seminar
 1998 Director, Winter Skin Seminar
 1999 -2000 Co-Director, Winter Skin Seminar
 2001 Director, Winter Skin Seminar
 2002 -2003 Co-Director, Winter Skin Seminar
 2004 Director, Winter Skin Seminar
 2005 -2006 Co-Director, Winter Skin Seminar
 2007 Director, Winter Skin Seminar

PEER-REVIEWED JOURNAL ARTICLES

1. Williams HJ, Samuelson CO, **Zone JJ**. (1979). Nodular nonsuppurative panniculitis associated with jejunoileal bypass surgery. *Arch Dermatol*, 115(9), 1091-3.
2. **Zone JJ**, LaSalle BA, Provost TT. (1980). Circulating immune complexes of IgA type in dermatitis herpetiformis. *J Invest Dermatol*, 75(2), 152-5.
3. Olmstead AD, **Zone JJ**, LaSalle B, Krueger GG. (1980). Immune complexes in the pathogenesis of hypergammaglobulinemic purpura. *J Am Acad Dermatol*, 3(2), 174-9.
4. Provost TT, **Zone JJ**, Synkowski D, Maddison PJ, Reichlin M. (1980). Unusual cutaneous manifestations of systemic lupus erythematosus: I. Urticaria-like lesions. Correlation with clinical and serological abnormalities. *J Invest Dermatol*, 75(6), 495-9.
5. Argyle JC, **Zone JJ**. (1981). Dermal erythropoiesis in a neonate. *Arch Dermatol*, 117(8), 492-4.
6. Clegg DO, **Zone JJ**, Piepkorn MW. (1982). Necrobiosis lipoidica associated with jejunoileal bypass surgery. *Arch Dermatol*, 118(2), 135-6.
7. Sanders SW, **Zone JJ**, Foltz RL, Tolman KG, Rollins DE. (1982). Hemolytic anemia induced by dapsone transmitted through breast milk. *Ann Intern Med*, 96(4), 465-6.
8. **Zone JJ**, LaSalle BA, Provost TT. (1982). Induction of IgA circulating immune complexes after wheat feeding in dermatitis herpetiformis patients. *J Invest Dermatol*, 78(5), 375-80.
9. **Zone J**, Ward J, Boyce E, Schupbach C. (1982). Penicillamine-induced pemphigus. *JAMA*, 247(19), 2705-7.
10. Piepkorn M, Brown C, **Zone J**. (1983). Auricular chondritis as a rheumatologic manifestation of Lucio's phenomenon: clinical improvement after plasmapheresis. *Ann Intern Med*, 98(1), 49-51.
11. Lane AT, Huff JC, **Zone JJ**, Weston WL. (1983). Class-specific antibodies to gluten in dermatitis herpetiformis. *J Invest Dermatol*, 80(5), 402-5.

12. Oikarinen AI, **Zone JJ**, Ahmed AR, Kiistala U, Uitto J. (1983). Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. *J Invest Dermatol*, 81(3), 261-6.
13. Park MS, Terasaki PI, Ahmed AR, **Zone J**. (1983). The 90% incidence of HLA antigen (Te24) in dermatitis herpetiformis. *Tissue Antigens*, 22(4), 263-6.
14. Petersen MJ, **Zone JJ**, Krueger GG. (1984). Development of a nude mouse model to study human sebaceous gland physiology and pathophysiology. *J Clin Invest*, 74(4), 1358-65.
15. Rom WN, Krueger G, **Zone J**, Attfield MD, Costello J, Burkart J, Turner ER. (1985). Morbidity survey of U.S. oil shale workers employed during 1948-1969. *Arch Environ Health*, 40(1), 58-62.
16. VanHale HM, Rogers RS 3rd, **Zone JJ**, Greipp PR. (1985). Pyostomatitis vegetans. A reactive mucosal marker for inflammatory disease of the gut. *Arch Dermatol*, 121(1), 94-8.
17. Servilla KS, Green JA, Williams HJ, **Zone JJ**. (1985). An unusual systemic staphylococcal illness with features of the mucocutaneous lymph node syndrome. *West J Med*, 142(2), 257-9.
18. Cunningham MJ, **Zone JJ**. (1985). Thyroid abnormalities in dermatitis herpetiformis. Prevalence of clinical thyroid disease and thyroid autoantibodies. *Ann Intern Med*, 102(2), 194-6.
19. Clegg DO, **Zone JJ**, Samuelson CO Jr, Ward JR. (1985). Circulating immune complexes containing secretory IgA in jejunoileal bypass disease. *Ann Rheum Dis*, 44(4), 239-44.
20. **Zone JJ**, Rom WN. (1985). Circulating immune complexes in asbestos workers. *Environ Res*, 37(2), 383-9.
21. Sanders SW, **Zone JJ**. (1986). The relationship between dapsone dose, serum concentration and disease severity in dermatitis herpetiformis. *Arzneimittelforschung*, 36(1), 146-9.
22. Oikarinen AI, Reunala T, **Zone JJ**, Kiistala U, Uitto J. (1986). Proteolytic enzymes in blister fluids from patients with dermatitis herpetiformis. *Br J Dermatol*, 114(3), 295-302.
23. Cunningham MJ, **Zone JJ**, Petersen MJ, Green JA. (1986). Circulating activated (DR-positive) T lymphocytes in a patient with autoeczematization. *J Am Acad Dermatol*, 14(6), 1039-41.
24. Clegg DO, Pincus SH, **Zone JJ**, Ward JR. (1986). Circulating HLA-DR bearing T cells: correlation with genetic rather than clinical variables. *J Rheumatol*, 13(5), 870-4.
25. Fortson JS, **Zone JJ**, Hammond ME, Groggel GC. (1986). Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone. *J Am Acad Dermatol*, 15(5 Pt 2), 1137-42.
26. Meyer LJ, Carioto L, **Zone JJ**. (1987). Dermatitis herpetiformis: extraction of intact IgA from granular deposits in dermal papillae. *J Invest Dermatol*, 88(5), 559-63.
27. Meyer LJ, **Zone JJ**. (1987). Familial incidence of dermatitis herpetiformis. *J Am Acad Dermatol*, 17(4), 643-7.
28. Meyer LJ, Piepkorn ME, Seuchter SA, Cannon-Albright LA, Bishop DT, **Zone JJ**, Skolnick MH. (1988). Genetic and epidemiologic evaluation of dysplastic nevus. *Pigment Cell Res, Supp 1*, 144-151.
29. Morrison LH, Labib RS, **Zone JJ**, Diaz LA, Anhalt GJ. (1988). Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. *J Clin Invest*, 81(6), 2023-6.
30. Piepkorn M, Meyer LJ, Goldgar D, Seuchter SA, Cannon-Albright LA, Skolnick MH, **Zone JJ**. (1989). The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. *J Am Acad Dermatol*, 20(3), 407-15.
31. Kadunce DP, Meyer LJ, **Zone JJ**. (1989). IgA class antibodies in dermatitis herpetiformis: reaction with tissue antigens. *J Invest Dermatol*, 93(2), 253-8.
32. **Zone JJ**, Taylor TB, Kadunce DP, Meyer LJ. (1990). Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. *J Clin Invest*, 85(3), 812-20.
33. Hendrix JD, Mangum KL, **Zone JJ**, Gammon WR. (1990). Cutaneous IgA deposits in bullous diseases function as ligands to mediate adherence of activated neutrophils. *J Invest Dermatol*, 94(5), 667-72.
34. Cannon-Albright LA, Goldgar DE, Wright EC, Turco A, Jost M, Meyer LJ, Piepkorn M, **Zone JJ**, Skolnick MH. (1990). Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. *Am J Hum Genet*, 46(5), 912-8.
35. Ahmed I, Piepkorn MW, Rabkin MS, Meyer LJ, Feldkamp M, Goldgar DE, Skolnick MH, **Zone JJ**. (1990). Histopathologic characteristics of dysplastic nevi. Limited association of conventional histologic criteria with melanoma risk group. *J Am Acad Dermatol*, 22(5 Pt 1), 727-33.
36. Meyer LJ, Taylor TB, Kadunce DP, **Zone JJ**. (1990). Two groups of bullous pemphigoid antigens are identified by affinity-purified antibodies. *J Invest Dermatol*, 94(5), 611-6.
37. Kadunce DP, Piepkorn MW, **Zone JJ**. (1990). Persistent melanocytic lesions associated with cosmetic tanning bed use: "sunbed lentiginos". *J Am Acad Dermatol*, 23(5 Pt 2), 1029-31.

38. Korman NJ, Eyre RW, **Zone J**, Stanley JR. (1991). Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. *J Invest Dermatol*, 96(2), 273-6.
39. Kadunce DP, Burr R, Gress R, Kanner R, Lyon JL, **Zone JJ**. (1991). Cigarette smoking: risk factor for premature facial wrinkling. *Ann Intern Med*, 114(10), 840-4.
40. Meyer LJ, Taylor TB, Kadunce DP, Thuong-Nguyen V, **Zone JJ**. (1991). Bullous pemphigoid antigens: extraction and degradation of antigens during epidermal preparation. *J Invest Dermatol*, 96(6), 991-3.
41. Ahmed I, Piepkorn M, Goldgar DE, Cannon-Albright LA, Meyer LJ, Skolnick MH, **Zone JJ**. (1991). HMB-45 staining of dysplastic melanocytic nevi in melanoma risk groups. *J Cutan Pathol*, 18(4), 257-60.
42. Kadunce DP, McMurry MP, Avots-Avotins A, Chandler JP, Meyer LJ, **Zone JJ**. (1991). The effect of an elemental diet with and without gluten on disease activity in dermatitis herpetiformis. *J Invest Dermatol*, 97(2), 175-82.
43. Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, **Zone JJ**, Skolnick MH. (1991). Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds. *J Natl Cancer Inst*, 83(23), 1726-33.
44. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olopade OI, Diaz MO, Kwiatkowski DJ, Piepkorn MW, **Zone JJ**, Skolnick MH. (1992). Assignment of a locus for familial melanoma MLM to chromosome 9p13-p22. *Science*, 258, 1148-1152.
45. Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, **Zone JJ**, Skolnick MH. (1992). Inheritance of nevus number and size in melanoma/DNS kindreds. *Cytogenet Cell Genet*, 59(2-3), 200-2.
46. Meyer LJ, Goldgar DE, Cannon-Albright LA, Piepkorn MW, **Zone JJ**, Risman MB, Skolnick MH. (1992). Number, size, and histopathology of nevi in Utah kindreds. *Cytogenet Cell Genet*, 59(2-3), 167-9.
47. Kasteler JS, Petersen MJ, Vance JE, **Zone JJ**. (1992). Circulating activated T lymphocytes in autoeczematization. *Arch Dermatol*, 128(6), 795-8.
48. Smith JB, Taylor TB, **Zone JJ**. (1992). The site of blister formation in dermatitis herpetiformis is within the lamina lucida. *J Am Acad Dermatol*, 27(2 Pt 1), 209-13.
49. Lookingbill DP, Abrams BB, Ellis CN, Jegasothy BV, Lucky AW, Ortiz-Ferrer LC, Savin RC, Shupack JL, Stiller MJ, **Zone JJ** et al. (1992). Inocoterone and acne. The effect of a topical antiandrogen: results of a multicenter clinical trial. *Arch Dermatol*, 128(9), 1197-200.
50. Smith JB, Tulloch JE, Meyer LJ, **Zone JJ**. (1992). The incidence and prevalence of dermatitis herpetiformis in Utah. *Arch Dermatol*, 128(12), 1608-10.
51. Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, **Zone JJ**. (1993). Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. *J Invest Dermatol*, 100(4), 349-55.
52. Smith EP, Taylor TB, Meyer LJ, **Zone JJ**. (1993). Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid. *J Invest Dermatol*, 101(4), 619-23.
53. Smith EP, Taylor TB, Meyer LJ, **Zone JJ**. (1993). Antigen identification in drug-induced bullous pemphigoid. *J Am Acad Dermatol*, 29(5 Pt 2), 879-82.
54. Dmochowski M, Hashimoto T, Bhogal BS, Black MM, **Zone JJ**, Nishikawa T. (1993). Immunoblotting studies of linear IgA disease. *J Dermatol Sci*, 6(3), 194-200.
55. Piepkorn MW, Barnhill RL, Cannon-Albright LA, Elder DE, Goldgar DE, Lewis CM, Maize JC, Meyer LJ, Rabkin MS, Sagebiel RW, Skolnick MH, **Zone JJ**. (1994). A multi-observer, population-based analysis of histologic dysplasia in melanocytic nevi. *J Am Acad Dermatol*, 30, 707-714.
56. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, **Zone JJ**, Skolnick MH, Cannon-Albright LA. (1994). Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. (β -2 Microglobulin, H₂O). *Nature Genetics*, 8, 22-26.
57. **Zone JJ**, Pazderka Smith E, Powell D, Taylor TB, Smith JB, Meyer LJ. (1994). Antigenic specificity of antibodies from patients with linear basement membrane deposition of IgA. *Dermatology*, 189 Suppl 1, 64-6.
58. Meyer LJ, **Zone JJ**. (1994). Genetics of cutaneous melanoma. *J Invest Dermatol*, 103, 112S-116S.
59. Cannon-Albright LA, Goldgar DE, Neuhausen S, Gruis NA, Anderson DE, Lewis CM, Kamb A, Weaver-Feldhaus J, Meyer LJ, **Zone JJ**, Skolnick MH. (1994). Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. *Genomics*, 23, 265-268.
60. Smith JB, Hansen CD, **Zone JJ**. (1994). Potassium iodide in the treatment of disseminated granuloma annulare. *J Am Acad Dermatol*, 30(5 Pt 1), 791-2.
61. Haftek M, **Zone JJ**, Taylor TB, Kowalewski C, Chorzelski TP, Schmitt D. (1994). Immunogold localization of the 97-kD antigen of linear IgA bullous dermatosis (LABD) detected with patients' sera. *J Invest Dermatol*, 103(5), 656-9.

62. Cannon-Albright LA, Meyer LJ, Goldgar DE, Lewis CM, McWhorter WP, Jost M, Harrison D, Anderson DE, **Zone JJ**, Skolnick MH. (1994). Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). *Cancer Res*, 54(23), 6041-4.
63. Shimizu K, Hashimoto T, Fukuda T, Watanabe K, Ishiko A, Niizeki H, Shimizu H, **Zone JJ**, Nishikawa T. (1995). A Japanese case of the fibrillar type of dermatitis herpetiformis. *Dermatology*, 191(2), 88-92.
64. Wisnieski JJ, Baer AN, Christensen J, Cupps TR, Flagg DN, Jones JV, Katzenstein PL, McFadden ER, McMillen JJ, Pick MA, Richmond GW, Simon SR, Smith HR, Sontheimer RD, Trigg LB, Weldon D, **Zone JJ**. (1995). Hypocomplementemic urticarial vasculitis syndrome. *Medicine*, 74(1), 24-41.
65. Darling TN, Cardenas AA, Beard JS, Sau P, Yee CL, **Zone JJ**, Yancey KB. (1995). A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens. *Arch Dermatol*, 131(12), 1438-42.
66. Chan LS, Traczyk T, Taylor TB, Eramo LR, Woodley DT, **Zone JJ**. (1995). Linear IgA bullous dermatosis. Characterization of a subset of patients with concurrent IgA and IgG anti-basement membrane autoantibodies. *Arch Dermatol*, 131(12), 1432-7.
67. Meyer LJ, Piepkorn M, Goldgar DE, Lewis CM, Cannon-Albright LA, **Zone JJ**, Skolnick MH. (1996). Interobserver concordance in discriminating clinical atypia of melanocytic nevi, and correlations with histologic atypia. *J Am Acad Dermatol*, 34(4), 618-25.
68. Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, **Zone JJ**. (1996). LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. *J Invest Dermatol*, 106(4), 734-8.
69. **Zone JJ**, Taylor TB, Kadunce DP, Chorzelski TP, Schachner LA, Huff JC, Meyer LJ, Petersen MJ. (1996). IgA antibodies in chronic bullous disease of childhood react with 97 kDa basement membrane zone protein. *J Invest Dermatol*, 106(6), 1277-80.
70. **Zone JJ**, Meyer LJ, Petersen MJ. (1996). Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. *Arch Dermatol*, 132(8), 912-8.
71. Egan CA, **Zone JJ**. (1997). An isolated scaling plaque on the scalp. *Arch Dermatol*, 133(10), 1304-5, 1307-8.
72. Smith JB, Smith SW, **Zone JJ**. (1998). Dermatitis herpetiformis and cigarette smoking. *Gut*, 43, 732.
73. **Zone JJ**, Taylor TB, Meyer LJ, Petersen MJ. (1998). The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. *J Invest Dermatol*, 110(3), 207-10.
74. Ishiko A, Shimizu H, Masunaga T, Yancey KB, Giudice GJ, **Zone JJ**, Nishikawa T. (1998). 97 kDa linear IgA bullous dermatosis antigen localizes in the lamina lucida between the NC16A and carboxyl terminal domains of the 180 kDa bullous pemphigoid antigen. *J Invest Dermatol*, 111(1), 93-6.
75. Shimizu H, Takizawa Y, Pulkkinen L, **Zone JJ**, Matsumoto K, Saida T, Uitto J, Nishikawa T. (1998). The 97 kDa linear IgA bullous dermatosis antigen is not expressed in a patient with generalized atrophic benign epidermolysis bullosa with a novel homozygous G258X mutation in COL17A1. *J Invest Dermatol*, 111(5), 887-92.
76. Egan CA, Taylor TB, Meyer LJ, Petersen MJ, **Zone JJ**. (1999). The immunoglobulin A antibody response in clinical subsets of mucous membrane pemphigoid. *Dermatology*, 198(4), 330-5.
77. Egan CA, Taylor TB, Meyer LJ, Petersen MJ, **Zone JJ**. (1999). Bullous pemphigoid sera that contain antibodies to BPAg2 also contain antibodies to LABD97 that recognize epitopes distal to the NC16A domain. *J Invest Dermatol*, 112(2), 148-52.
78. Egan CA, Grant WJ, Morris SE, Saffle JR, **Zone JJ**. (1999). Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. *J Am Acad Dermatol*, 40(3), 458-61.
79. Egan CA, Hanif N, Taylor TB, Meyer LJ, Petersen MJ, **Zone JJ**. (1999). Characterization of the antibody response in oesophageal cicatricial pemphigoid. *Br J Dermatol*, 140(5), 859-64.
80. Egan CA, Martineau MR, Taylor TB, Meyer LJ, Petersen MJ, **Zone JJ**. (1999). IgA antibodies recognizing LABD97 are predominantly IgA1 subclass. *Acta Derm Venereol*, 79(5), 343-6.
81. Egan CA, Taylor TB, Meyer LJ, Petersen MJ, **Zone JJ**. (1999). IgA1 is the major IgA subclass in cutaneous blood vessels in Henoch-Schonlein purpura. *Br J Dermatol*, 141(5), 859-62.
82. Egan CA, Florell SR, **Zone JJ**. (1999). Localized bullous pemphigoid in a patient with B-cell lymphoma. *South Med J*, 92(12), 1220-2.
83. Egan CA, Meadows KP, **Zone JJ**. (2000). Plasmapheresis as a steroid saving procedure in bullous pemphigoid. *Int J Dermatol*, 39(3), 230-5.
84. Lewis C, Book L, Black J, Sawitzke A, Cannon-Albright L, **Zone J**, Neuhausen S. (2000). Celiac disease and human leukocyte antigen genotype: accuracy of diagnosis in self-diagnosed individuals, dosage effect, and sibling risk. *J Pediatr Gastroenterol Nutr*, 31(1), 22-7.

85. Florell SR, Egan CA, Gregory MC, **Zone JJ**, Petersen MJ. (2001). Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. *J Cutan Med Surg*, 5(1), 33-6.
86. Neuhausen SL, Feolo M, Farnham J, Book L, **Zone JJ**. (2001). Linkage analysis of HLA and candidate genes for celiac disease in a North American family-based study. *BMC Med Genet*, 2(1), 12.
87. Book L, Hart A, Black J, Feolo M, **Zone JJ**, Neuhausen SL. (2001). Prevalence and clinical characteristics of celiac disease in Down's syndrome in a US study. *Am J Med Genet*, 98(1), 70-4.
88. Florell SR, Holden J, Meyer L, Samlowski W, Cannon-Albright L, Newhausen S, **Zone J**, Leachman S. (2001). Proliferation status of nevi in Utah kindred members with and without CDKN2A mutations. *J Invest Dermatol*, 117(2), 520.
89. Florell SR, **Zone JJ**, Gerwels JW. (2001). Basal cell carcinomas are populated by melanocytes and Langerhans [correction of Langerhan's] cells. *Am J Dermatopathol*, 23(1), 24-8.
90. Lebwohl MG, Daniel CR, Leyden J, Mormon M, Shavin JS, Tschen E, Weiss J, **Zone J**. (2001). Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. *Int J Dermatol*, 40(5), 358-60.
91. Egan CA, Smith EP, Taylor TB, Meyer LJ, Samowitz WS, **Zone JJ**. (2001). Linear IgA bullous dermatosis responsive to a gluten-free diet. *Am J Gastroenterol*, 96(6), 1927-9.
92. Feolo M, Fuller TC, Taylor M, **Zone JJ**, Neuhausen SL. (2001). A strategy for high throughput HLA-DQ typing. *J Immunol Methods*, 258(1-2), 65-71.
93. Neuhausen SL, Weizman Z, Camp NJ, Elbedour K, Sheffield VC, **Zone JJ**, Carmi R. (2002). HLA DQA1-DQB1 genotypes in Bedouin families with celiac disease. *Hum Immunol*, 63(6), 502-7.
94. Neuhausen SL, Feolo M, Camp NJ, Farnham J, Book L, **Zone JJ**. (2002). Genome-wide linkage analysis for celiac disease in North American families. *Am J Med Genet*, 111(1), 1-9.
95. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, **Zone JJ**. (2002). Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. *J Am Acad Dermatol*, 47(4), 548-52.
96. Book L, **Zone JJ**, Neuhausen SL. (2003). Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. *Am J Gastroenterol*, 98(2), 377-81.
97. McKenna JK, Hull CM, **Zone JJ**. (2003). Argiria associated with colloidal silver supplementation. *Int J Dermatol*, 42(7), 549.
98. **Zone JJ**, Egan CA, Taylor TB, Meyer LJ. (2004). IgA autoimmune disorders: development of a passive transfer mouse model. *J Investig Dermatol Symp Proc*, 9(1), 47-51.
99. Florell SR, Meyer LJ, Boucher KM, Porter-Gill PA, Hart M, Erickson J, Cannon-Albright LA, Pershing LK, Harris RM, Samlowski WE, **Zone JJ**, Leachman SA. (2004). Longitudinal assessment of the nevus phenotype in a melanoma kindred. *J Invest Dermatol*, 123(3), 576-82.
100. Call TR, Boucher KM, Whiting BL, Hart M, Newman K, Kinney AY, Bowen GM, **Zone JJ**, Branson D, Leachman SA. (2004). Motivating factors for attendance of skin cancer screenings. *J Am Acad Dermatol*, 51(4), 642-4.
101. **Zone JJ**. (2005). Skin manifestations of celiac disease. *Gastroenterology*, 128(4 Pt 2), S87-91.
102. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, **Zone JJ**, Samlowski WE, Leachman SA. (2005). Population-based analysis of prognostic factors and survival in familial melanoma. *J Clin Oncol*, 23(28), 7168-77.
103. Florell SR, Meyer LJ, Boucher KM, Hart M, Cannon-Albright LA, Harris RM, Grossman D, Samlowski WE, **Zone JJ**, Brinton JP, Leachman SA. (2005). Nevus Distribution in a Utah Melanoma Kindred with a Temperature-Sensitive CDKN2A Mutation. *J Invest Dermatol*, 125(6), 1310-2.
104. Eliason MJ, Larson AA, Florell SR, **Zone JJ**, Cannon-Albright LA, Samlowski WE, Leachman SA. (2006). Population-Based Prevalence of CDKN2A Mutations in Utah Melanoma Families. *J Invest Dermatol*, 126(3), 660-6.
105. Samolitis NJ, Hull CM, Leiferman KM, **Zone JJ**. (2006). Dermatitis herpetiformis and partial IgA deficiency. *J Am Acad Dermatol*, 54(5 Suppl), S206-9.
106. Florell SR, Cessna M, Lundell RB, Boucher KM, Bowen GM, Harris RM, Petersen MJ, **Zone JJ**, Tripp S, Perkins SL. (2006). Usefulness (or lack thereof) of immunophenotyping in atypical cutaneous T-cell infiltrates. *Am J Clin Pathol*, 125(5), 727-36.
107. Donaldson MR, **Zone JJ**, Schmidt LA, Taylor TB, Neuhausen SL, Hull CM, Meyer LJ. (2007). Epidermal Transglutaminase Deposits in Perilesional and Uninvolved Skin in Patients with Dermatitis Herpetiformis. *J Invest Dermatol*, 127(5), 1268-71.
108. Garner CP, Ding YC, Steele L, Book L, Leiferman K, **Zone JJ**, Neuhausen SL. (2007). Genome-wide linkage analysis of 160 North American families with celiac disease. *Genes Immun*, 8(2), 108-14.

109. Taintor AR, Leiferman KM, Hashimoto T, Ishii N, **Zone JJ**, Hull CM. (2007). A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. *J Am Acad Dermatol*, 56(5 Suppl), S73-6.
110. Donaldson MR, Firth SD, Wimpee H, Leiferman KM, **Zone JJ**, Horsley W, O'gorman MA, Jackson WD, Neuhausen SL, Hull CM, Book LS. (2007). Correlation of duodenal histology with tissue transglutaminase and endomysial antibody levels in pediatric celiac disease. *Clin Gastroenterol Hepatol*, 5(5), 567-73.
111. **Zone JJ**, Taylor T, Hull C, Schmidt L, Meyer L. (2007). IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. *J Invest Dermatol*, 127(5), 1167-74.
112. Donaldson MR, Book LS, Leiferman KM, **Zone JJ**, Neuhausen SL. (2008). Strongly positive tissue transglutaminase antibodies are associated with Marsh 3 histopathology in adult and pediatric celiac disease. *J Clin Gastroenterol*, 42(3), 256-60.
113. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, **Zone JJ**, Leachman SA. (2008). Increased Melanocytic Nevi and Nevus Density in a G-34T CDKN2A/p16 Melanoma-Prone Pedigree. *J Invest Dermatol*, 128(8), 2122-5.
114. Hull CM, Liddle M, Hansen N, Meyer LJ, Schmidt L, Taylor T, Jaskowski TD, Hill HR, **Zone JJ**. (2008). Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. *Br J Dermatol*, 159(1), 120-4.
115. Neuhausen SL, Steele L, Ryan S, Mousavi M, Pinto M, Osann KE, Flodman P, **Zone JJ**. (2008). Co-occurrence of celiac disease and other autoimmune diseases in celiacs and their first-degree relatives. *J Autoimmun*, 31(2), 160-5.

NON PEER-REVIEWED JOURNAL ARTICLES

1. **Zone JJ**. (1989). Dermatitis Herpetiformis: Pathogenesis and treatment. *Autoimmunity Forum*, 1(2), 2-4.
2. **Zone JJ**. (2001). Clinical spectrum, pathogenesis and treatment of linear IgA bullous dermatosis. *J Dermatol*, 2811, 651-653.

REVIEW ARTICLES

1. **Zone JJ**, Meyer LJ. (1989). Dermatitis herpetiformis. *Immunol Ser*, 46, 565-82.
2. Smith EP, **Zone JJ**. (1993). Dermatitis herpetiformis and linear IgA bullous dermatosis. *Dermatol Clin*, 11(3), 511-26.
3. Piepkorn M, Cannon-Albright LA, Meyer LJ, Goldgar DE, **Zone JJ**, Skolnick MH. (1994). Genetic Predisposition to Malignant Melanoma. *Melanoma Letter*, 12, 1-4.
4. Smith EP, Fankhanel KJ, **Zone JJ**. (1995). Linear IgA Bullous Dermatitis. *Clinical Dermatology, 22nd Revision*, 1-10.
5. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, **Zone JJ**, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB. (1998). Epitope spreading: lessons from autoimmune skin diseases. *J Invest Dermatol*, 110(2), 103-9.
6. Egan CA, **Zone JJ**. (1999). Linear IgA bullous dermatosis. *Int J Dermatol*, 38(11), 818-27.
7. Egan CA, O'Reilly MA, Meadows KP, **Zone JJ**. (2000). Relapsing Henoch-Schonlein purpura associated with Pseudomonas aeruginosa pyelonephritis. *J Am Acad Dermatol*, 42(2 Pt 2), 381-3.
8. **Zone JJ**. (2001). Clinical spectrum, pathogenesis and treatment of linear IgA bullous dermatosis. *J Dermatol*, 28(11), 651-3.
9. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T, Kirtschig G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich MP, Mondino BJ, Prost-Squarcioni C, Rogers RS 3rd, Setterfield JF, West DP, Wojnarowska F, Woodley DT, Yancey KB, Zillikens D, **Zone JJ**. (2002). The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. *Arch Dermatol*, 138(3), 370-9.
10. Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, **Zone JJ**, Noyes RD, Bowen GM, Leachman SA. (2003). Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. *J Clin Oncol*, 21(11), 2179-86.
11. Bowen AR, Smith L, **Zone JJ**. (2003). Scleredema adultorum of Buschke treated with radiation. *Arch Dermatol*, 139(6), 780-4.
12. **Zone JJ**, Hull CM. (2004). Warning: bread may be harmful to your health. *American Academy of Dermatology Journal*, 51(1 Suppl), S27-8.

BOOKS

Edited Books

1. Callen JP, Jorizzo JL, Greer KE, Penneys NS, Piette WW, **Zone JJ** (Eds.). (1988). *Dermatological Signs of Internal Disease*. Saunders.

2. Callen JP, Jorizzo JL, Greer KE, Penneys NS, Piette WW, **Zone JJ** (Eds.). (1995). *Dermatological Signs of Internal Disease*. Saunders.
3. Callen JP, Jorizzo JL, Bologna JL, Piette WW, **Zone JJ** (Eds.). (2003). *Dermatological Signs of Internal Disease*. Saunders.

BOOK CHAPTERS

1. **Zone JJ**, Provost TT. (1979). Bullous diseases. In *Dermatology Update* (pp. 361-389).
2. **Zone JJ**. (1980). Cutaneous effects of shale oil. In *Health Implications of New Energy Technologies* (pp. 457-461). Technomic Pub Co.
3. **Zone JJ**. (1982). Pemphigus and pemphigoid. In *Current Therapy* (pp. 677-679).
4. **Zone JJ**. (1982). Pustular psoriasis. In *Clinical Dermatology* (1, pp. 1-5).
5. **Zone JJ**. (1982). Pustulosis palmaris et plantaris. In *Clinical Dermatology* (1, pp. 1-6).
6. **Zone JJ**. (1983). Dermatitis herpetiformis. In *Current Therapy* (pp. 616-618).
7. Petersen MJ, **Zone JJ**. (1984). Dermatitis herpetiformis - a challenge in immunodermatology. In *Current Concepts in Skin Disorders* (5, pp. 15-19).
8. **Zone JJ**, Provost TT. (1985). Bullous diseases: Pemphigus, bullos pemphigoid, epidermolysis bullosa acquisita, herpes gestationis, benign mucous membrane pemphigoid, chronic bullous disease of childhood, bullous erythema multiforme, and dermatitis herpetiformis. In *Dermatology* (pp. 557-589).
9. **Zone JJ**, Petersen MJ. (1985). Dermatitis Herpetiformis. In *Current Therapy in Dermatology* (pp. 66-70).
10. **Zone JJ**, Petersen MJ. (1985). Dermatitis herpetiformis. In *Pathogenesis of Skin Disease* (pp. 159-183).
11. **Zone JJ**, Petersen MJ. (1987). Dermatitis herpetiformis. In *Current Therapy in Internal Medicine* (2, pp. 119-122).
12. **Zone JJ**. (1988). Bullous Diseases. In Callen, JP; Jorizzo JL; Greer KE; Penneys NS; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (pp. 332-343). Saunders.
13. **Zone JJ**. (1988). Chronic bullous dermatosis of childhood. In *Current Therapy in Dermatology* (2, pp. 60-62).
14. **Zone JJ**. (1988). Cutaneous Diseases Associated with Gastrointestinal Abnormalities. In Callen, JP; Jorizzo JL; Greer KE; Penneys NS; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (pp. 215-227). Saunders.
15. **Zone JJ**. (1988). Mast Cell Disease. In Callen, JP; Jorizzo JL; Greer KE; Penneys NS; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (pp. 327-331). Saunders.
16. **Zone JJ**. (1988). Neurocutaneous Disease. In Callen, JP; Jorizzo JL; Greer KE; Penneys NS; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (pp. 306-319). Saunders.
17. **Zone JJ**. (1988). The Hair, Nails and Mucous Membranes. In Callen, JP; Jorizzo JL; Greer KE; Penneys NS; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (pp. 344-354). Saunders.
18. Kadunce DP, **Zone JJ**. (1990). Bullous Diseases. In *Conn's Current Therapy* (pp. 759-762).
19. **Zone JJ**. (1991). Dermatitis herpetiformis. In *Immunologic Diseases of the Skin* (pp. 335-345).
20. Smith EP, **Zone JJ**. (1993). Bullous Diseases. In *Dermatitis herpetiformis and linear IgA bullous dermatosis* (pp. 511-526).
21. **Zone JJ**. (1994). Bullous Disease. In *Dermatological Signs of Internal Disease* (2nd edition, pp. 96-108).
22. **Zone JJ**. (1994). Cutaneous disease associated with gastrointestinal abnormalities. In *Dermatological Signs of Internal Disease* (2nd edition, pp. 219-232).
23. **Zone JJ**. (1994). Cutaneous disease associated with gastrointestinal abnormalities. In Callen JP, Jorizzo JL, Greer KE, Penneys NS, Piette WW, Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (2nd, pp. 219-232). Philadelphia: W. B. Saunders Co.
24. **Zone JJ**. (1994). Neurocutaneous disease. In *Dermatological Signs of Internal Disease* (2nd edition, pp. 322-336).
25. **Zone JJ**. (1995). Bullous Disease. In Callen, JP; Jorizzo JL; Greer KE; Penneys NS; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (Second Edition, pp. 96-108). Saunders.
26. **Zone JJ**. (1995). Cutaneous Disease Associated with Gastrointestinal Abnormalities. In Callen, JP; Jorizzo JL; Greer KE; Penneys NS; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (Second Edition, pp. 219-232). Saunders.
27. **Zone JJ**. (1995). Neurocutaneous Disease. In Callen, JP; Jorizzo JL; Greer KE; Penneys NS; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (Second Edition, pp. 322-336). Saunders.
28. Smith EP, **Zone JJ**. (1996). Linear IgA Bullous Dermatitis. In *Cutaneous Medicine and Surgery: An Integrated Program in Dermatology* (pp. 698-703).
29. **Zone JJ**. (1998). Progress in immunoglobulin A dermatoses. In *Dermatology at the Millennium*.
30. Egan CA, **Zone JJ**. (1999). Linear IgA Bullous Dermatitis. In *Int J Dermatol* (38, pp. 818-827).
31. Nemzer PG, Egan CA, **Zone JJ**. (2000). Linear IgA Bullous Dermatitis. In Jordan RE (Ed.), *Atlas of Bullous Diseases*. Philadelphia, PA: W. B. Saunders Co.

32. Bowen, AR, **Zone JJ**. (2003). Bullous Diseases. In Callen, JP; Jorizzo JL; Bologna JL; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (Third Edition, pp. 81-93). Saunders.
33. Herron MD, **Zone JJ**. (2003). Cutaneous Diseases Associated with Gastrointestinal Abnormalities. In Callen, JP; Jorizzo JL; Bologna JL; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (Third Edition, pp. 199-210). Saunders.
34. Liu CM, **Zone JJ**. (2003). Neurocutaneous Disease. In Callen, JP; Jorizzo JL; Bologna JL; Piette WW; Zone JJ (Eds.), *Dermatological Signs of Internal Disease* (Third Edition, pp. 287-300). Saunders.
35. Harris RM, **Zone JJ**. (2006). Dermatitis herpetiformis. In Lebwohl, Heymann, Berth-Jones and Coulson (Eds.), *Treatment of Skin Disease* (2nd Edition, pp. 156-158). Elsevier Mosby.
36. Hull C, **Zone JJ**. (2008). Dermatitis herpetiformis and linear IgA bullous dermatosis. In Bologna J, Jorizzo J, Rapini R (Eds.), *Dermatology* (2nd Edition, Volume 1, pp. 447-456). Elsevier Mosby.

CONFERENCE PROCEEDINGS

1. **Zone JJ**, Weidner M. (1985). The treatment of secondary skin infections with Bactroban ointment: A vehicle-controlled study. *Bactroban (mupirocin). Proceedings of an International Symposium*, 263-265.

OTHER (Commentary/Letters/Editorials/Case Reports/Video/Film)

Letters

1. **Zone JJ**. (1981). Potassium iodide and vasculitis [Letter to the editor]. *Arch Dermatol*, 117(12), 758-9.
2. **Zone JJ**. (1982). Regional body temperature and disease [Letter to the editor]. *N Engl J Med*, 306(4), 239.
3. Smith JB, Fowler JB, **Zone JJ**. (1994). The effect of ibuprofen on serum dapsone levels and disease activity in dermatitis herpetiformis [Letter to the editor]. *Arch Dermatol*, 130(2), 257-9.
4. Egan CA, Rallis TM, **Zone JJ**. (1998). Multiple scrotal lymphangiomas (lymphangiectases) treated by carbon dioxide laser ablation [Letter to the editor]. *Br J Dermatol*, 139(3), 561-2.
5. Smith JB, Smith SB, **Zone JJ**. (1998). Dermatitis herpetiformis and cigarette smoking [Letter to the editor]. *Gut*, 43(5), 732.
6. Egan CA, Meadows KP, **Zone JJ**. (1999). Ulcerative colitis and immunobullous disease cured by colectomy [Letter to the editor]. *Arch Dermatol*, 135(2), 214-5.
7. Florell SR, **Zone JJ**, Gerwels JW. (2001). American J Dermatopathology [Letter to the editor]. *Am J Dermatopathol*, 23(6), 558-560.
8. Egan CA, Reddy D, Nie Z, Taylor TB, Schmidt LA, Meyer LJ, Petersen MJ, Hashimoto T, Marinkovich MP, **Zone JJ**. (2001). IgG anti-LABD97 antibodies in bullous pemphigoid patients' sera react with the mid-portion of the BPAg2 ectodomain [Letter to the editor]. *J Invest Dermatol*, 116(2), 348-50.
9. Book L, Neuhausen S, **Zone J**. (2002). How should we define celiac disease? [Letter to the editor]. *J Pediatr Gastroenterol Nutr*, 34(1), 92.
10. Florell SR, Boucher KM, Holden JA, Meyer LJ, Samlowski WE, Cannon-Albright LA, **Zone JJ**, Leachman SA. (2002). Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers [Letter to the editor]. *J Invest Dermatol*, 118(2), 386-7.
11. Hull CM, McKenna JK, **Zone JJ**. (2003). Topical corticosteroids and bullous pemphigoid [Letter to the editor]. *Arch Dermatol*, 139(2), 225-6.
12. Hall CS, **Zone JJ**, Hull CM. (2008). Treatment of recalcitrant disseminated granuloma annulare with hydroxyurea [Letter to the editor]. *J Am Acad Dermatol*, 58(3), 525.

ORAL PRESENTATIONS

Meeting Presentations (Not Published Abstracts and Not Unpublished Posters)

International

- | | |
|------|---|
| 1992 | International Congress of Dermatology, New York, NY |
| 1997 | International Congress of Dermatology, Sydney Australia |
| 2000 | Westwood Squibb Fall Conference, Los Cabos, Mexico |

National

- | | |
|------------|--|
| 1979 -1994 | American Academy of Dermatology |
| 1991 | Dermatology Foundation, Palm Springs, CA |
| 1992 | Dermatology Continuing Medical Education Course, Orlando, FL |

1993 Symposium on Severe Dermatoses, Maui, HI
1996 Dermatology Foundation, Carmel, CA
1997 Celiac Disease Foundation, Studio City, CA
1998 -2002 American Academy of Dermatology
2003 "Celiac Disease and the Skin." Celiac Disease Foundation, Los Angeles, CA
2003 "Celiac Disease and the Skin." Celiac Disease Program, Columbia University

Local/Regional

1984 -1994 Internal Medicine Symposium, American Academy of Dermatology.
1990 Family Practice Refresher Course, SUNY at Syracuse
1990 -1999 Westwood Squibb Winter Skin Seminar, CO
1991 -1994 Internal Medicine Refresher Course, Sarasota, FL
1991 -1994 Internal Medicine Continuing Medical Education Conference, Snowbird, UT
1993 -1995 University of Utah Internal Medicine Symposium, Park City, UT
1993 Gluten Intolerance Group, Seattle, WA
1996 -2002 Intermountain Dermatology Society, Sun Valley, ID
1999 Weber Immunology Retreat, Heber, UT
1999 -2001 University of Utah Internal Medicine Symposium, Park City, UT
1999 Internal Medicine Research Retreat, Salt Lake City, UT
1999 OB-GYN Annual Update, Park City, UT
2000 -2002 Internal Medicine, Advances In, Park City, UT
2000 Westwood Squibb Winter Skin Seminar, Snowbird, UT
2001 Noah Worcester Dermatological Society, Laguna Niguel, CA
2001 Westwood Squibb Winter Skin Seminar, CO
2001 Proctor Gamble Lectureship, Cincinnati, OH
2002 Fall Clinical Dermatology Conference, Las Vegas, NV
2002 Medicus Winter Skin Seminar, Vail, CO

Invited/Visiting Professor Presentations

International

1993 Keio University, Tokyo Japan
1996 Kurume University, Kurume, Japan
1996 Chinese-Japanese Dermatologic Society, Beijing, China
1996 Japanese Bullous Disease Group Meeting, Hikone, Japan
1998 Salzburg Austria, Bullous Disease Symposium
2006 International Symposium on Celiac Disease, New York City, NY
2007 World Congress of Dermatology, Buenos Aires, Argentina
2008 International Investigative Dermatology Auto Immune Disease Satellite Meeting, Otsu, Japan

National

1990 Arizona Dermatologic Society, Tucson, AZ
1993 Mayo Clinic, O'Leary Meeting, Rochester, MN
1994 Alabama Dermatologic Society, Sandestin, FL
2000 Harvard Medical School
2003 "Does IgA cause skin disease?" Bernice Fine Lectureship, University of Louisville
2004 NIH Consensus Development Conference on Celiac Disease
2006 American Professors of Dermatology, Chicago, IL
2006 Fall Clinical Dermatology Conference, Las Vegas, NV
2007 American Academy of Dermatology, Internal Medicine Symposium, National Meeting, Washington, D.C.
2007 American Academy of Dermatology, Internal Medicine Symposium, Summer Meeting, New York City, NY
2008 American Academy of Dermatology, Internal Medicine Symposium, National Meeting, San Antonio, TX
2008 American Academy of Dermatology, Internal Medicine Symposium, Summer Meeting, Chicago, IL
2008 34th Annual Society for Pediatric Dermatology Meeting, Snowbird, UT
2008 Fall Clinical Dermatology Conference, Las Vegas, NV

Local/Regional

1991 University of Miami, Miami, FL
1992 NIH Consensus Conference on Melanoma, Washington DC
1992 Southeastern Consortium for Medical Education, Charleston, SC
1993 University of Oregon, Portland, OR
1993 Educational Resource Development Counsel
1993 University of Washington, Pommerening Lectureship, Seattle, WA
1993 New York University, New York, NY
1993 Women's Advisory Counsel Focus Luncheon
1993 Hospital Board
1993 Classics Club, Salt Lake City
1994 Utah State Annual Lupus Seminar
1994 Rotary Club of Salt Lake City
1994 University Hospital Women's Auxiliary
1994 Gluten Intolerance Group, Salt Lake City
1994 -1998 Valley of Sun Dermatology Conference, Phoenix, AZ
1994 Winter Meeting of the Health Sciences Counsel, Palm Springs, CA
1995 Medical College of Wisconsin, Milwaukee, WI
1995 Johns Hopkins University, Baltimore, MD, Israel Zeligman Lectureship
1995 Milwaukee Dermatologic Society, Milwaukee WI
1995 South Central Dermatologic Congress XXVII, Aspen, CO
1996 Case Western Reserve University, Cleveland, OH
1996 Northwestern University, Chicago, IL
1996 University of California- Los Angeles, Los Angeles, CA
1996 University of Pennsylvania, Philadelphia, PA
1997 University of Louisville, Louisville KY
1997 University of Texas Southwestern, Fox Lectureship, Dallas, TX
1997 Southwest Dermatology Society, El Paso, TX
1997 Southern Medical Association, Charlotte, NC
1998 University of Colorado, Henry Lewis Lectureship, Denver, CO
1998 Medical University of South Carolina, Charleston SC
1998 Cleveland Clinic, Cleveland, OH
1998 Harvard Medical School, Boston MA
1998 Dartmouth-Hitchcock Medical Center, Lebanon, NH
2002 Geisinger University
2006 Duke University, Visiting Professor Presentation, Durham, NC

Grand Rounds Presentations

2003 Does IgA Cause Skin Disease?, Medical College of Wisconsin Grand Rounds